Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams and Wilkins
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer (EBC). Here, we report 5-year efficacy results from a prespecified overall survival (OS) interim analysis. In the intent-to-treat population, with a median follow-up of 54 months, the benefit of abemaciclib was sustained with hazard ratios of 0.680 (95% CI, 0.599 to 0.772) for IDFS and 0.675 (95% CI, 0.588 to 0.774) for DRFS. This persistence of abemaciclib benefit translated to continuous separation of the curves with a deepening in 5-year absolute improvement in IDFS and DRFS rates of 7.6% and 6.7%, respectively, compared with rates of 6% and 5.3% at 4 years and 4.8% and 4.1% at 3 years. With fewer deaths in the abemaciclib plus ET arm compared with the ET-alone arm (208 v 234), statistical significance was not reached for OS. No new safety signals were observed. In conclusion, abemaciclib plus ET continued to reduce the risk of developing invasive and distant disease recurrence beyond the completion of treatment. The increasing absolute improvement at 5 years is consistent with a carryover effect and further supports the use of abemaciclib in patients with high-risk EBC. © 2024 American Society of Clinical Oncology.
Açıklama
Anahtar Kelimeler
Abemaciclib, Aromatase İnhibitor, Tamoxifen, Abemaciclib, Aminopyridine Derivative, Antineoplastic Agent, Benzimidazole Derivative, Epidermal Growth Factor Receptor 2, Erbb2 Protein, Human, İmmunological Adjuvant, Adjuvant Chemotherapy, Adult, Aged, Article, Cancer Hormone Therapy, Cohort Analysis, Comparative Study, Controlled Study, Distant Recurrence Free Survival, Drug Efficacy, Drug Withdrawal, Female, Follow Up, Gastrointestinal Disease, Hormone Receptor-Positive, Her2-Negative Breast Cancer, Human, İnfection, Major Clinical Study, Male, Mortality Rate, Overall Survival, Phase 3 Clinical Trial, Treatment Outcome, Breast Tumor, Tumor Recurrence, Adjuvants, Immunologic, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Breast Neoplasms, Female, Humans, Neoplasm Recurrence, Local, Receptor, Erbb-2
Kaynak
Journal of Clinical Oncology
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
42
Sayı
9
